At-a-glance: SGLT2 inhibitors, GLP-1 agonists, insulin vs insulin, and more-a look at what’s new, what’s next.
Click through the slides above for our monthly at-a-glance reviews of recent studies in T2DM. Among our October topics:
• CV and renal outcomes with SGLT2 inhibitors
• Insulins go head to head
• Add-on options for metforminSee the slide legends for links to article summaries.
T2D Study Guide for October: SGLT2 Inhibitors, GLP-1 Agonists, Insulins head-to-head, and CV Outcomes
Cardiovascular Mortality and Morbidity in Patients With Type 2 Diabetes Following Initiation of Sodium-Glucose Co-Transporter-2 Inhibitors Versus Other Glucose-Lowering Drugs (CVD-REAL Nordic): A Multinational Observational Analysis.ABSTRACT
Effects of Empagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes and Established Cardiovascular Disease: An Exploratory Analysis From the EMPA-REG OUTCOME Randomised, Placebo-Controlled Trial. ABSTRACT.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ABSTRACT.
Day-to-Day Fasting Glycaemic Variability in DEVOTE: Associations With Severe Hypoglycaemia and Cardiovascular Outcomes (DEVOTE 2). ABSTRACT
Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People With Type 2 Diabetes.
Effects on the Incidence of Cardiovascular Events of the Addition of Pioglitazone Versus Sulfonylureas in Patients With Type 2 Diabetes Inadequately Controlled With Metformin (TOSCA.IT): A Randomised, Multicentre Trial.ABSTRACT
